Home » Diffuse large B-cell lymphoma: here is a promising new drug

Diffuse large B-cell lymphoma: here is a promising new drug

by admin
Diffuse large B-cell lymphoma: here is a promising new drug

Diffuse large B-cell lymphoma represents an aggressive and complex form of blood cancer, constituting the most widespread variant of non-Hodgkin lymphoma in Italy. Treatment options have seen limited progress over the past two decades. Although a considerable percentage of patients respond positively to initial treatment, nearly 40% show no response or experience a relapse.

Diffuse large B-cell lymphoma: here is polatuzumab

For these reasons, medical oncologists positively welcome AIFA’s approval of a new drug, polatuzumabwhich in combination with other therapies (rituximab, cyclophosphamide, doxorubicin and prednisone – R-CHP) reduces the risk of disease progression, relapse or death by 27% compared to standard of care.

“Today we celebrate an important step forward in the fight against diffuse large B-cell lymphoma,” he comments Maurizio Martelli, full professor and director of the Hematology Unit of the University Hospital Policlinico Umberto I of the Sapienza University of Rome. «After almost twenty years since the introduction of new therapeutic options, the AIFA decision opens the doors to a new era of treatment for recently diagnosed patients. The combination of polatuzumab and R-CHP represents a new resource that could significantly improve outcomes and bring tangible benefits to those facing this type of aggressive lymphoma.”

«This new therapy, arrived after decades of attempts, increases patients’ chances of recovery with the first line of treatment, thus reducing the need to resort to second and third line therapies, which are often very burdensome and demanding for patients and for the sustainability of the healthcare system” he adds Antonello Pintomedical director of the National Cancer Institute, G. Pascale Foundation, IRCCS of Naples.

See also  Steal and pass it off as your own as a business model - health check

«It is a therapeutic modality that not only reduces the risk of relapse, but also contributes to preserving and improving the quality of life of those who face this difficult challenge. This result is the result of research and incessant commitment in the field of oncology and encourages us to continue in the mission of providing increasingly effective treatments and offering concrete hope for the future.”

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy